<DOC>
	<DOCNO>NCT02040883</DOCNO>
	<brief_summary>Efficacy safety Tandospirone combine Atypical Antipsychotic drug Improve Cognitive function Schizophrenia</brief_summary>
	<brief_title>Tandospirone Combined With Atypical Antipsychotic Drugs Schizophrenia</brief_title>
	<detailed_description>With atypical antipsychotic control group , evaluate cognitive function schizophrenia patient antipsychotic combine 5-Hydroxytryptamine 1A ( 5-HT1A ) receptor partial agonist tandospirone</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Tandospirone</mesh_term>
	<criteria>Diagnostic Statistical Manual Mental DisordersIV Edition ( DSMIV ) diagnostic criterion schizophrenia patient . 1865 year ( include 18 65 ) , male female . Treated stable dose AAPD least three month . Informed consent obtain ( patient acute phase schizophrenia , capacity , guardian need sign inform consent ) . PANSS negative score ≤60 . Combined AxisⅠmental illness schizophrenia ; Taking mood stabilizer , antidepressant , anticholinergic anxiolytic drug , drug improve cognitive function ; Suicidal tendency ; Have severe unstable heart , liver , kidney , endocrine , blood medical disease patient Clinically significant ECG laboratory abnormality Glaucoma epilepsy ; Unsupervised unable take prescribed medication ; History alcohol drug abuse ; Allergic ; Pregnant lactate woman ; Patients participate clinical trial month ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Tandospirone</keyword>
	<keyword>Cognitive Therapy</keyword>
</DOC>